Hadani, Samera S.
HRN: 18-89-39 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/25/2022
CEFUROXIME 500MG (TAB)
05/25/2022
05/31/2022
ORAL
500mg
Q12
S/P Exlap
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes